Avid­i­ty clam­ors for $150M raise on heels of pos­i­tive da­ta read­out

And just like oth­er com­pa­nies, Avid­i­ty Bio­sciences is go­ing for a raise af­ter a pos­i­tive da­ta read­out.

The biotech an­nounced just one day af­ter re­veal­ing some pos­i­tive pre­lim­i­nary da­ta that it was ask­ing in­vestors for $150 mil­lion via a pub­lic raise. It kept its state­ment short, say­ing that it plans to of­fer the $150 mil­lion worth of shares in com­mon stock and give un­der­writ­ers 30 days to grab an ad­di­tion­al 15% on top of what’s in the pub­lic of­fer­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER